LOS ANGELES CALIFORNIA, November 2, 2021GTX Corp (OTC: GTXO) (“the Company”), a pioneer in the fields of: health & safety wearable GPS human and asset tracking systems and personal protective medical equipment and supplies, today announced it has begun selling Halberd Corporation (OTC-PINK: HALB) Vita-Shield-MaxTM all in one immune support nutraceutical which helps maximize one’s natural immunity defenses.
In addition to selling this propriety blend of natural immunity booster as part of GTX’s longevity revolution initiative, GTX and Halberd are also planning to work together on products for various neurodegenerative diseases such as Alzheimer’s and Traumatic Brain Injury, among others. Many of these diseases are prevalent among seniors, active duty and veteran soldiers, participants in contact sports, and millions of people in the general population. Halberd and GTX intend to work together to utilize their combined technologies and years of experience in the field to develop superior diagnostics/treatments for these diseases and afflictions.
“Since a large percentage of our patented GPS SmartSole customer base is afflicted with Alzheimer’s, dementia, autism, and traumatic brain injury, it makes a lot of sense for us to continue to expand our partnerships, product offerings and solutions to address these issues for this growing global market,” commented GTX Corp CEO, Patrick Bertagna.
GTX also recently signed an agreement with LifeConnect to explore integrating IoT wearable sensors into its GPS SmartSole platform. This will be used as a communications gateway sending vital biometric data along with GPS coordinates to the cloud, leveraging the LifeConnect and Life365 Health backend platforms and GTX’s GPS 4G SmartSole platform.
GTX Corp is a For-Profit with Purpose Company which has an extensive line of health & safety products, patent portfolio, is a proud U.S. military contractor and has multiple wearable tracking products sold through its online store, Amazon and authorized resellers and distributors servicing customers across the globe.
MetAlert (OTC: MLRT) and its subsidiaries occupy a commanding position in the design, development, manufacturing, distribution, sales, and licensing of GPS wearable technology, asset recovery services, wandering assistive technology, and health data collection and monitoring. The Company delivers comprehensive global solutions encompassing logistics, hardware, software, and connectivity.
Notable achievements include GunAlert the world’s first all in one firearm safety solution gun lock with patented motion sensor and GPS theft recovery. And the groundbreaking GPS SmartSole®, a fusion of Dr. Scholl’s comfort with LoJack’s tracking prowess. It stands as the world’s inaugural invisible wearable tracking device, designed for individuals susceptible to wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based model thrives on technology innovation fortified by intellectual property safeguards. The company boasts international distribution channels serving customers across 40 countries, alongside its role as a U.S. Military Government contractor. In addition to public health entities, MetAlert caters to municipalities, emergency and law enforcement agencies, private educational institutions, assisted living facilities, NGOs, senior care residences, consumers, and small enterprises.
General information, investor relations, wholesale licensing, consumer purchase:
213.489.3019 | Info@MetAlert.com | IR@MetAlert.com | Contact Us
MetAlert.com | Mygunalert.com | Track My Workforce | GPS SmartSole.com
MetAlert United Kingdom– In the UK, MetAlert operates from its London office.
Please contact: Nelson Skip Riddle | Email: NSRiddle@MetAlert.com | Tel: +44 7785 364100
Level 2 Security (Wholly owned subsidiary) Email: contactus@level2sec.com | www.mygunalert.com | www.ifitmoves.com
Forward Looking Statements
This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by MetAlert considering its experience and perception of current conditions and expected future developments, as well as other factors that MetAlert believes are appropriate in the circumstances. Many factors could cause MetAlert’s actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are outlined in MetAlert’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained on the SEC Website). These factors should be considered carefully, and readers should not rely on MetAlert’s forward-looking statements. MetAlert has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required.
Disclaimer: MetAlert does not warrant or represent that the unauthorized use of materials drawn from this document’s content will not infringe the rights of third parties who are not owned or affiliated by MetAlert. Further, MetAlert cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.